These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15102864)

  • 1. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.
    Ma JD; Nafziger AN; Bertino JS
    J Clin Pharmacol; 2004 May; 44(5):447-56. PubMed ID: 15102864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic polymorphisms in drug-metabolizing enzymes].
    Saruwatari J; Nakagawa K; Ishizaki T
    Nihon Rinsho; 2002 Jan; 60(1):58-63. PubMed ID: 11808340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of antipsychoatics.
    Ozaki N
    Nagoya J Med Sci; 2004 May; 67(1-2):1-7. PubMed ID: 15279062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
    Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
    Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of genotyping and phenotyping of biotransformation in therapeutic drug monitoring].
    Barré J
    Therapie; 2001; 56(3):251-5. PubMed ID: 11475803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the world of cytochrome P450 enzymes.
    Frye RF
    Mol Interv; 2004 Jun; 4(3):157-62. PubMed ID: 15210869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
    Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 polymorphisms and response to antipsychotic therapy.
    Scordo MG; Spina E
    Pharmacogenomics; 2002 Mar; 3(2):201-18. PubMed ID: 11972442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current availability of genetic information of drug metabolizing enzymes, particularly on cytochrome P450(CYP)].
    Yamazoe Y; Nagata K
    Nihon Rinsho; 2001 Aug; 59(8):1614-23. PubMed ID: 11519169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics in HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nacher I; Rendón A; Soriano V
    AIDS Rev; 2005; 7(2):103-12. PubMed ID: 16092504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.